Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, announced that John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will present at Citi’s 15th Annual BioPharma Virtual Conference today, Tuesday, September 8, 2020 at 2:20pm ET.
CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will present at Citi’s 15th Annual BioPharma Virtual Conference today, Tuesday, September 8, 2020 at 2:20pm ET.
About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/disc-medicine-to-present-at-citis-15th-annual-biopharma-virtual-conference-301124704.html
View original content to download multimedia:SOURCE Disc Medicine
